Compounds > dioxolane-thymine
Page last updated: 2024-11-08

dioxolane-thymine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dioxolane-thymine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID451593
CHEMBL ID304445
SCHEMBL ID8612207
SCHEMBL ID1129570
MeSH IDM0499146

Synonyms (32)

Synonym
136982-89-3
(-)-d-.beta.-dioxolane t
(-)-1-[(2r,4r)-2-hydroxymethyl)-1,3-dioxan-4-yl]thymine
(-)-d-.beta.-dioxolane-thymine
DOT ,
dioxolane-thymine
dioxolane thymidine
dioxolane t
(+/-)-dioxolane-t
2,4(1h,3h)-pyrimidinedione, 1-[(2r,4r)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-methyl-
(+/-)-dot
(+/-)-1-[(2beta,4beta)-2-(hydroxymethyl)-4-dioxolanyl] thymine
1-[(2r,4r)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-methyl-pyrimidine-2,4-dione
beta-d-dioxolane thymine
CHEMBL304445
(-)-1-((2r,4r)-2-(hydroxymethyl)-1,3-dioxan-4-yl)thymine
wt6gzm4ya8 ,
(-)-d-beta-dioxolane-thymine
(-)-d-beta-dioxolane t
(+-)-dot
2,4(1h,3h)-pyrimidinedione, 1-((2r,4r)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methyl-
unii-wt6gzm4ya8
(+-)-1-((2beta,4beta)-2-(hydroxymethyl)-4-dioxolanyl) thymine
(+-)-dioxolane-t
SCHEMBL8612207
SCHEMBL1129570
4-hydroxy-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-5-methylpyrimidin-2(1h)-one
DTXSID90925930
BCAWWPAPHSAUQZ-RNFRBKRXSA-N
(-)-1-[(2r,4r)-2-(hydroxymethyl)-4-dioxolanyl]thymine
2,4(1h,3h)-pyrimidinedione, 1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methyl-, (2r-cis)-
1-((2r,4r)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-5-methylpyrimidine-2,4(1h,3h)-dione

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profiles of D-DOT in serum and urine were adequately described by a two-compartment open pharmacokinetic model."( Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
Asif, G; Chu, CK; Delinsky, D; Hurwitz, SJ; McClure, HM; Narayanasamy, J; Obikhod, A; Schinazi, RF, 2007)		0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID369078Antiviral activity against HIV1 LAI infected in CEM cells2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies.
AID406035AUC in rhesus monkey at 33.3 mg/kg, po2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406040Tlag in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID152650Cytotoxicity in peripheral blood mononuclear cells(PBM).1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.
AID406044Drug elimination in rhesus monkey assessed as beta-dioxolane-thymine-glucuronide elimination at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406039Oral bioavailability in rhesus monkey at 33.3 mg/kg2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406031Volume of distribution at steady state in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406038Cmax in rhesus monkey at 33.3 mg/kg, po2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406043Drug elimination in rhesus monkey assessed as beta-dioxolane-thymine-glucuronide elimination at 33.3 mg/kg, po2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406024Antiviral activity against Lamivudine resistant HIV1 with reverse transcriptase M184V mutation in human PBMC2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406057Drug elimination in monkey urine after 30 days2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406025Antiviral activity against tenofovir resistant HIV1 with reverse transcriptase K65R mutation in human PBMC2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID369081Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies.
AID406032AUC in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406034Renal clearance in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406046Drug level in rhesus monkey cerebrospinal fluid at 33.3 mg/kg, iv after 2 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406045Drug level in rhesus monkey cerebrospinal fluid at 33.3 mg/kg, iv after 1 hr2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406028Systemic clearance in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406026Antiviral activity against didanosine resistant HIV1 with reverse transcriptase L74V mutation in human PBMC2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406048Drug level in rhesus monkey cerebrospinal fluid at 33.3 mg/kg, po after 2 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406060Ratio of drug level in cerebrospinal fluid to plasma of rhesus monkey at 33.3 mg/kg, po after 1 hr2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406033Mean residence time in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406058Ratio of drug level in cerebrospinal fluid to plasma of rhesus monkey at 33.3 mg/kg, iv after 1 hr2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406029Central volume of distribution in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID369079Cytotoxicity against human PBM cells after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies.
AID406042Biodistribution in in rhesus monkey urine assessed as dose recovered unchanged at 33.3 mg/kg, iv after 8 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406037Tmax in rhesus monkey at 33.3 mg/kg, po2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406047Drug level in rhesus monkey cerebrospinal fluid at 33.3 mg/kg, po after 1 hr2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID229224Cytotoxicity in vero cells.1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.
AID406036Mean residence time in rhesus monkey at 33.3 mg/kg, po2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406059Ratio of drug level in cerebrospinal fluid to plasma of rhesus monkey at 33.3 mg/kg, iv after 2 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406023Antiviral activity against HIV12007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406041Biodistribution in in rhesus monkey urine assessed as dose recovered unchanged at 33.3 mg/kg, po after 8 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID154973Effective concentration against HIV-1 in peripheral blood mononuclear cells(PBM).1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.
AID369080Cytotoxicity against human CEM cells after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
5'-O-Aliphatic and amino acid ester prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine (DOT): synthesis, anti-HIV activity, cytotoxicity and stability studies.
AID406061Ratio of drug level in cerebrospinal fluid to plasma of rhesus monkey at 33.3 mg/kg, po after 2 hrs2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID154934Effective concentration against HIV-1 strain LAV in human peripheral blood mononuclear (PBM) cells.1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships.
AID406030Terminal phase half life in rhesus monkey at 33.3 mg/kg, iv2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
AID406027Antiviral activity against zidovudine resistant HIV1 in human PBMC2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's4 (57.14)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymine
[no description available]		3.1450pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.0310dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.9240azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
phosphoramidic acid
phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds		2.4520phosphoric acid derivative
amdoxovir
amdoxovir: structure in first source; RN given refers to (2R-cis)-isomer		2.0310
troxacitabine
troxacitabine: shows good anti-HIV activity without cytotoxicity		1.9810carbohydrate derivative;
nucleobase-containing molecular entity
2-aminopurine dioxolane
(4-2-aminopurin-9-yl)-1,3-dioxolane-2-methanol: structure in first source		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		07.0310